Methods for treating breast and other cancers by targeting argininosuccinate synthetase 1-deficiency
US11311608B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 1, 2016 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Apr 1, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y305/03006
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Autophagy is the principal catabolic response to nutrient starvation. However, excessive autophagy can be cytotoxic or cytostatic, and contribute to cell death, but its mechanism of induction remains elusive. Here, it was demonstrated that prolonged arginine starvation by ADI-PEG20 induced an autophagy-dependent death of argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Consequently, arginine depleting agents such as ADI-PEG20 may be used in methods for killing one or more argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Further, abundance of ASS1 was either low or absent in more than 60% of 149 random breast cancer biosamples, which could be exploited as candidates for arginine starvation therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.